Welch Daniel G
SEC-identified person · CIK 1206199 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Structure Therapeutics Inc. GPCR | Director | filed 2023 - 2026 |
| Ultragenyx Pharmaceutical Inc. RARE | Director | filed 2015 - 2026 |
| Prothena Corp plc PRTA | Director | filed 2024 - 2026 |
| Panacea Acquisition Corp PANA | Director | filed 2021 - 2024 |
| Seagen Inc. SGEN | Director | filed 2007 - 2023 |
| Intercept Pharmaceuticals, INC. ICPT | Director | filed 2015 - 2020 |
| Avexis, Inc. AVXS | Director | filed 2016 - 2018 |
| Hyperion Therapeutics INC HPTX | Director | filed 2012 - 2015 |
| Intermune INC ITMN | Director · Charman, CEO and President | filed 2006 - 2014 |
| Corium International, Inc. CORI | Director | filed 2014 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.